Pharmacotherapy. 2000 Feb;20(2):130-9.

Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists.

Source

Drug Information Center, Hartford Hospital, Connecticut 06102-5037, USA.

Abstract

Over the past 4 years, six angiotensin II receptor antagonists (ARBs) were approved for treating essential hypertension. They differ with respect to dosing, metabolism, elimination, clinical efficacy, and investigational applications. Candesartan cilexetil is the only prodrug among the agents. Losartan is distinguished from other ARBs by cytochrome P450 (CYP) 3A4- and CYP2C9-mediated biotransformation to its active metabolite EXP-3174. No ARB requires dosage adjustment for renal impairment, but the initial dose of losartan should be reduced 50% in hepatically impaired patients. None of the drugs is significantly cleared by hemodialysis. Completion of continuing trials will elucidate the drugs' role in treating heart failure, cerebral stroke, and myocardial infarction.

PMID:: 10678291; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

High Blood Pressure - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. [J Hum Hypertens. 2000]
Review Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH. J Hum Hypertens. 2000 Apr; 14 Suppl 1:S73-86.
Review Newly emerging pharmacologic differences in angiotensin II receptor blockers. [Am J Hypertens. 2000]
Review Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Oparil S. Am J Hypertens. 2000 Jan; 13(1 Pt 2):18S-24S.
Review Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? [Am J Cardiol. 1999]
Review Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
Unger T. Am J Cardiol. 1999 Nov 18; 84(10A):9S-15S.
Review Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). [Mini Rev Med Chem. 2003]
Review Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Swamy KM, Lin MJ, Sun CM. Mini Rev Med Chem. 2003 Sep; 3(6):621-31.
Review The comparative pharmacology of angiotensin II receptor antagonists. [Blood Press Suppl. 2001]
Review The comparative pharmacology of angiotensin II receptor antagonists.
Burnier M, Maillard M. Blood Press Suppl. 2001; 1:6-11.

See reviews... See all...

Cited by 2 PubMed Central articles

Differential pharmacology and benefit/risk of azilsartan compared to other sartans. [Vasc Health Risk Manag. 2012]
Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
Kurtz TW, Kajiya T. Vasc Health Risk Manag. 2012; 8:133-43. Epub 2012 Feb 28.
Review The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. [Vasc Health Risk Manag. 2009]
Review The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.
Del Fiorentino A, Cianchetti S, Celi A, Dell'Omo G, Pedrinelli R. Vasc Health Risk Manag. 2009; 5(1):233-42. Epub 2009 Apr 8.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II...
Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists.
Pharmacotherapy. 2000 Feb ;20(2):130-9.

PubMed
Weight loss, weight maintenance, and improved cardiovascular risk factors after ...
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Obes Res. 2000 Jan ;8(1):49-61.

PubMed
Methadone maintenance treatment: outcomes from the Otago methadone programme.
Methadone maintenance treatment: outcomes from the Otago methadone programme.
N Z Med J. 1999 Nov 26 ;112(1100):442-5.

PubMed
The activation loop of phosphatidylinositol phosphate kinases determines signali...
The activation loop of phosphatidylinositol phosphate kinases determines signaling specificity.
Mol Cell. 2000 Jan ;5(1):1-11.

PubMed
Factor analysis of craniofacial morphology in cleft lip and palate in man.
Factor analysis of craniofacial morphology in cleft lip and palate in man.
Arch Oral Biol. 1976 ;21(8):465-72.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: